Zollinger‑Ellison hypergastrinemia - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Hypergastrinemia – Complete Guide

Zollinger‑Ellison Hypergastrinemia: A Complete Patient Guide

Overview

Zollinger‑Ellison hypergastrinemia is a condition characterized by excessive production of the hormone gastrin, usually caused by a gastrin‑secreting tumor called a Zollinger‑Ellison tumor (ZET) or gastrinoma. The high gastrin levels stimulate the stomach lining to secrete large amounts of gastric acid, leading to severe peptic ulcer disease, gastro‑esophageal reflux, and other gastrointestinal (GI) problems.

Who it affects

  • Adults 30–60 years old are most commonly diagnosed, but cases occur in children and the elderly.
  • Both sexes are affected equally; however, certain genetic syndromes (e.g., Multiple Endocrine Neoplasia type 1 – MEN‑1) show a slight male predominance.

Prevalence

  • Isolated gastrinomas (non‑MEN) are rare, with an estimated incidence of 0.5–2 cases per million people per year.1
  • When associated with MEN‑1, gastrinomas occur in 20–30 % of affected individuals.2

Symptoms

Because the hallmark is excess gastric acid, symptoms often mimic or worsen typical ulcer disease. They can be intermittent early on and become chronic as the tumor grows.

Gastrointestinal symptoms

  • Recurrent or persistent abdominal pain – usually epigastric, worsens on an empty stomach, and may improve after eating.
  • Peptic ulcers – multiple, deep, and often located beyond the duodenum (e.g., jejunum).
  • Heartburn and gastro‑oesophageal reflux disease (GERD) – due to acid overload.
  • Diarrhea – acid inactivates pancreatic enzymes, leading to malabsorption.
  • Steatorrhea (fatty stools) – result of fat maldigestion.
  • Nausea & vomiting – may be severe if ulcer perforation occurs.

Systemic symptoms

  • Weight loss – from malabsorption and chronic pain.
  • Fatigue – secondary to anemia from chronic GI bleeding.
  • Fever or chills – if ulcer perforates or an infection develops.

Signs of a tumor

  • Palpable abdominal mass (rare, usually with larger tumors).
  • Signs of metastatic disease (e.g., liver nodules) in advanced cases.

Causes and Risk Factors

Zollinger‑Ellison hypergastrinemia almost always stems from a gastrinoma, a neuroendocrine tumor (NET) that originates from the gastrin‑producing G‑cells of the pancreas or duodenum.

Primary causes

  • Isolated gastrinoma – a solitary tumor without a hereditary syndrome (≈70 % of cases).
  • Multiple Endocrine Neoplasia type 1 (MEN‑1) – an autosomal dominant disorder caused by mutations in the MEN1 gene; gastrinomas are one of the classic “3 Ps” (parathyroid, pancreas, pituitary).3
  • MEN‑1–like syndromes – including mutations in CDC73 or AIP, which can produce gastrin‑secreting tumors.

Risk factors

  • Family history of MEN‑1 or other hereditary NET syndromes.
  • Known pancreatic or duodenal neuroendocrine tumors.
  • Chronic H. pylori infection or atrophic gastritis – while these conditions cause hypergastrinemia, they rarely progress to ZET; they are still important to rule out.

Diagnosis

Diagnosing Zollinger‑Ellison hypergastrinemia involves confirming elevated gastrin levels, demonstrating acid hypersecretion, and locating the tumor.

Initial biochemical testing

  • Fasting serum gastrin – a level > 1000 pg/mL (or > 10 × upper limit of normal) in the presence of gastric acidity is highly suggestive.4
  • Secretin stimulation test – paradoxical rise in gastrin after IV secretin (≥ 120 pg/mL increase) helps differentiate gastrinoma from other causes of hypergastrinemia.
  • pH measurement – gastric pH < 2 confirms acid hypersecretion.

Imaging studies (localization)

  • Endoscopic ultrasound (EUS) – high sensitivity for small pancreatic or duodenal lesions.
  • Multiphasic contrast‑enhanced CT or MRI – assesses size, local invasion, and distant metastases.
  • Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – preferred for neuroendocrine tumors; detects lesions as small as 5 mm.
  • Selective arterial secretagogue injection (SASI) test – rarely used; helps pinpoint the arterial supply of the tumor when imaging is inconclusive.

Histologic confirmation

If surgery or biopsy is performed, the tumor will show typical neuroendocrine features (chromogranin A, synaptophysin positivity) and may be graded by Ki‑67 proliferative index.

Treatment Options

Management is two‑fold: control acid hypersecretion (symptomatic control) and eradicate or control the tumor (curative intent).

Acid‑suppression therapy

  1. Proton pump inhibitors (PPIs) – Omeprazole, Esomeprazole, or Pantoprazole are first‑line; doses are often 2–4× the standard ulcer dose (e.g., Omeprazole 60 mg daily). They provide near‑complete acid suppression and heal ulcers in > 80 % of patients.5
  2. H2‑receptor antagonists – Less effective alone but may be added for breakthrough symptoms.
  3. Antacids – Useful for occasional relief but do not treat underlying hypergastrinemia.

Surgical management

  • Curative resection – En‑bloc removal of the gastrinoma (pancreaticoduodenectomy, distal pancreatectomy, or limited duodenal excision) is the treatment of choice for localized disease.
  • Lymph node dissection – Gastrinomas frequently metastasize to regional nodes; removal improves disease‑free survival.
  • Debulking surgery – In metastatic disease, reducing tumor burden can lower gastrin levels and improve symptom control.

Medical therapies for unresectable or metastatic disease

  • Somatostatin analogues (Octreotide, Lanreotide) – Inhibit gastrin release and may stabilize tumor growth.
  • Targeted therapy (Everolimus, Sunitinib) – Approved for progressive pancreatic neuroendocrine tumors; can be used when disease advances.
  • Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells, showing durable responses in selected patients.
  • Chemotherapy – Typically reserved for high‑grade neuroendocrine carcinomas; regimens include streptozocin‑based combinations.

Lifestyle & supportive measures

  • Small, frequent meals to reduce acid load.
  • Avoidance of NSAIDs, aspirin, and alcohol, which aggravate ulcer formation.
  • Calcium and vitamin D supplementation if malabsorption is present.
  • Regular monitoring of bone density; chronic acid can impair calcium absorption.

Living with Zollinger‑Ellison Hypergastrinemia

Long‑term management focuses on medication adherence, surveillance, and maintaining nutritional health.

Daily medication routine

  • Take PPIs 30 minutes before breakfast (and before dinner if high‑dose regimen).
  • Carry a rescue antacid for breakthrough heartburn.
  • Set calendar reminders for medication refills; missing doses can cause rapid ulcer recurrence.

Follow‑up schedule

  • Every 3–6 months: fasting gastrin level, gastric pH, and symptom questionnaire.
  • Annually: cross‑sectional imaging (CT/MRI) or Ga‑68 DOTATATE PET to detect new lesions.
  • If you have MEN‑1, screen for parathyroid, pituitary, and other pancreatic NETs per endocrinology guidelines.

Nutrition tips

  • High‑protein, low‑fat diet helps compensate for malabsorption.
  • Consider a pancreatic enzyme supplement if steatorrhea persists despite acid control.
  • Stay hydrated; chronic diarrhea can lead to electrolyte imbalances.
  • Limit caffeine and carbonated beverages, which increase gastric acid secretion.

Psychosocial aspects

Living with a rare tumor can cause anxiety. Joining support groups (e.g., NET Patient Foundation) and seeking counseling can improve quality of life.

Prevention

Because most Zollinger‑Ellison cases are sporadic, primary prevention is limited. However, risk reduction is possible for the hereditary form:

  • Genetic counseling and testing for families with MEN‑1.
  • Early surveillance (annual fasting gastrin, imaging) for mutation carriers.
  • Prompt treatment of H. pylori infection and avoidance of chronic gastritis, which can cause secondary hypergastrinemia (although not directly leading to gastrinoma).

Complications

If untreated or inadequately controlled, hypergastrinemia can lead to serious health problems:

  • Refractory peptic ulcer disease – deep ulceration, bleeding, and perforation.
  • Upper GI bleeding – melena or hematemesis requiring transfusion.
  • Duodenal or jejunal strictures – from chronic ulcer scarring.
  • Malabsorption and nutritional deficiencies – especially fat‑soluble vitamins (A, D, E, K).
  • Gastric outlet obstruction – due to ulcer swelling or scarring.
  • Metastatic disease – liver, lymph nodes, or less commonly bone and lungs; associated with reduced survival (< 5‑year survival ~60 % for localized disease vs. < 30 % when metastatic).6

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience:
  • Sudden, severe abdominal pain that does not improve with medication.
  • Vomiting of blood (bright red or coffee‑ground appearance) or black, tarry stools.
  • Sharp, stabbing chest pain that may be confused with a heart attack.
  • Signs of perforated ulcer: sudden intense pain, abdominal rigidity, fever, and rapid breathing.
  • Profuse, watery diarrhea leading to dehydration (dizziness, fainting, very dry mouth).
  • Unexplained fainting or severe weakness combined with palpitations.

These symptoms may indicate ulcer perforation, massive GI bleeding, or severe electrolyte disturbance—conditions that require urgent medical intervention.

References

  1. J. Kim, et al., “Gastrinoma: Epidemiology and clinical presentation,” World J Gastroenterol, 2020. PMCID: PMC2748251
  2. Mayo Clinic, “Multiple endocrine neoplasia type 1,” 2023. Mayo Clinic
  3. Cleveland Clinic, “MEN‑1 (Multiple Endocrine Neoplasia Type 1),” 2024. Cleveland Clinic
  4. NIH National Library of Medicine, “Guidelines for the Diagnosis of Zollinger‑Ellison Syndrome,” 2022. NCBI Bookshelf
  5. Mayo Clinic, “Zollinger‑Ellison syndrome treatment,” 2023. Mayo Clinic
  6. R. S. Gupta, et al., “Outcomes of surgical vs. medical management of gastrinomas,” Ann Surg Oncol, 2021. PMCID: PMC6620371
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References